Oral Anticoagulants in Development
- 1 January 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 66 (11), 1411-1429
- https://doi.org/10.2165/00003495-200666110-00001
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- New anticoagulantsJournal of Thrombosis and Haemostasis, 2005
- A review of the oral direct thrombin inhibitor ximelagatran: Not yet the end of the warfarin era…American Heart Journal, 2005
- New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarinBritish Journal of Pharmacology, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Prevention of Venous Thromboembolism Following Orthopaedic SurgeryDrugs, 2004
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementNew England Journal of Medicine, 2003